News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: Week's China Life Science Deals Total $795 Million



11/22/2016 8:18:25 AM

Asymchem Laboratories of Tianjin raised $125 million in a Shenzhen IPO that it will use to expand its CMO operations; BeyondSpring Pharma, a virtual US-China cancer company, filed to stage a $100 million IPO on the NASDAQ exchange; SciClone Pharma, a US company marketing drugs in China, received an unsolicited $570 million acquisition offer from Ally Bridge affiliates; Uni-Bio Science of Hong Kong and Luqa Pharma of China formed a China dermatology co-marketing partnership; Omixon, a Budapest molecular diagnostics company, partnered with Taiwan's TBG Biotechnology to distribute Omixon's genotyping products in China; researchers at Chengdu's Sichuan University became the first to inject CRISPR–Cas9 edited genes into a patient; Athenex, a US-China pharma, will collaborate with Eli Lilly in a two-drug gastric cancer clinical trial; Hutchison China MediTech reported positive data from a first-in-human Phase I trial of a Syk inhibitor; ASLAN Pharma of Singapore engaged JHL Biotech of Taiwan and China to provide biologic process development services; and NeuroMetrix, a US medical device maker, announced it will launch its peripheral neuropathy diagnostic in China.

Read at ChinaBio Today


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES